The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
metformin alleviates drug-induced osteoarthritis (OA)-like change in mice knee joint through
activating autophagy and downregulating apoptosis. Metformin exerts its protective effects
against OA through the AMPKa2/ SIRT1 pathway. Metformin suppresses IL-1β-induced oxidative
and osteoarthritis-like inflammatory changes by enhancing the SIRT3/PINK1/Parkin signaling
pathway, thereby indicating metformin's potential in prevention and treatment of
osteoarthritic joint disease.